VERIGRAFT has brought together the teams working on TECVI-2 for the trial’s first cross-functional progress meeting in Gothenburg, strengthening coordination across partners and preparing for the milestones ahead.
VERIGRAFT recently brought together the teams dedicated to TECVI-2, the company’s pivotal Phase II/III clinical trial of P-TEV, for the first cross-functional progress meeting in Gothenburg.
Representatives from Junta de Andalucía, TFS HealthScience, Aptio Group Sweden, Techedge Solution, and VERIGRAFT met over two days to review progress, align processes across organisations and strengthen cross-functional collaboration across the trial programme.
The meeting resulted in a number of insightful discussions, constructive decisions and valuable knowledge sharing across the participating teams. It also provided an important opportunity to coordinate priorities and prepare for the milestones ahead as TECVI-2 progresses across countries.
TECVI-2 is VERIGRAFT’s pivotal Phase II/III clinical trial evaluating P-TEV, the company’s personalised tissue-engineered vein with a functioning valve, for patients with chronic venous insufficiency (CVI).
“The energy and can-do attitude across the team really stood out. Together with the open discussions and strong knowledge sharing, it demonstrated a shared commitment to delivering a high-quality trial of P-TEV across countries,” said Sarah Josefsson, Clinical Trials Director, VERIGRAFT.
VERIGRAFT thanks all participating teams for their preparation, engagement and contribution to two productive days in Gothenburg, and looks forward to continuing to drive the next phase of the trial forward together.